Abstract
An enzyme immunoassay for prostatic acid phosphatase (PAP) has been assessed. An upper limit of normal is set at 1.8 μg/1. There is a very low incidence of raised levels in chronic disease or cancers other than those of the prostate. Patients with well-controlled prostatic cancer have levels < 1.8 μg/1 and show little variation about their own mean. PAP can rise exponentially with a doubling time of 1–5 months. This assay is unlikely to increase the detection of asymptomatic prostatic cancer as 66% of T 0–2N xM 0 cases had PAP < 1.8 μg/l. The main advantages over routine enzyme assays are its sensitivity and accuracy in the lower range.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
